ABSTRACT
Background Point-of-care platelet function tests are used by anaesthetists and surgeons to create risk management plans for patients who have recently taken antiplatelet medication. Thromboelastography (TEG), one method of determining platelet function, sometimes takes >60 minutes to produce results. Previous studies have shown a novel parameter, area under the curve at 15 minutes (AUC15), correlates with clinical outcomes but used privately-owned, custom-made software to calculate AUC15. This study aimed to create a formula that clinicians can use to approximate AUC15 which correlates to the most widely used measure of platelet function, percentage of platelet aggregation.
Methods Platelet function after 15 minutes can be approximated by the equation: AUC15 = 225(tan(θ)) where θ = α(MAADP/MAThrombin). A retrospective database review was performed on eligible platelet function tests that assessed ADP receptor inhibition on a TEG 6s Hemostasis Analyzer (Haemonetics®) across 15 months. Results were analysed using a bivariate scatter plot with linear regression line and a two-tailed Pearson correlation coefficient was calculated.
Results Forty-seven tests were retrieved, of which, forty-five were eligible for analysis. Pearson two-tailed correlation coefficient showed that AUC15 correlated significantly with percentage of platelet aggregation (R = 0.748, 95% CI [0.582, 0.854], p < 0.001).
Conclusion This study creates the first practical method for clinicians to approximate platelet function on TEG analysers after 15 minutes, instead of >60 minutes, using routinely generated outputs and a calculator. Clinicians who use this method will afford themselves more time to create risk management plans for patients which may improve patient outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for this work.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
DECLARATIONS OF INTEREST: None
CRediT AUTHOR STATEMENT: Elliott Sharp: Conceptualization, methodology, formal analysis, investigation, writing – original draft, writing – review & editing.
Data Availability
Data is available upon request to the corresponding author.
6. GLOSSARY
- ADP
- adenosine diphosphate
- PFT
- Platelet function tests
- TEG
- Thromboelastography
- AUC15
- Area under the curve at 15 minutes
- MA
- Maximum amplitude
- α angle
- Angle of thrombin curve between 2-20mm amplitude
- R time
- Latency time between start of test until 2mm amplitude on the thrombin curve is achieved
- θ angle
- An approximation of the α angle for the ADP curve
